Relmada Therapeutics Inc (RLMD) Stock AnalysisRLMDStock AnalysisRelmada Therapeutics Inc

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Relmada Therapeutics Inc (RLMD) is a good buy right now due to its current price of $4.33, which is significantly below analyst price targets ranging from $12 to $19. The stock's RSI of 15.812 indicates it is oversold, suggesting a potential rebound. Additionally, insider buying has surged by 1133.44% over the last month, indicating strong confidence from those within the company. However, the main risk is the negative earnings trend, with a net income loss of $19,051,956 reported in Q1 2026.